🇺🇸 FDA
Pipeline program

BGB-16673

BGB-16673-107

Phase 1 small_molecule active

Quick answer

BGB-16673 for Chronic Spontaneous Urticaria is a Phase 1 program (small_molecule) at BeOne Medicines with 1 ClinicalTrials.gov record(s).

Program details

Company
BeOne Medicines
Indication
Chronic Spontaneous Urticaria
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials